Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

Filter Results:

Show Only Available Presentations

  • +

    ESMO Colloquium supported by Lilly Oncology in collaboration with MSD - How to best use immune checkpoint inhibitors in NSCLC: Single agents or combined with chemotherapy?

    • Type: ESMO Colloquium
    • Presentations: 7
    • Coordinates: 4/10/2019, 04:45 - 06:15, Room A
    • +

      Are immune checkpoints (ICPs) better as single agent, doublet ICPs or combined with chemo +/- anti-angiogenics?

      12:30 - 12:50  |  Presenter: Solange Peters

      • Abstract
      • Presentation
      • Slides

      No abstract available for this presentation

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

  • +

    Opening and welcome

    • Type: Opening and welcome
    • Presentations: 4
    • Coordinates: 4/10/2019, 13:30 - 13:45, Room B
  • +

    Proffered Paper session I

    • Type: Proffered Paper session
    • Presentations: 8
    • Coordinates: 4/10/2019, 16:30 - 18:15, Room C
    • +

      LBA4 - Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study

      17:45 - 18:00  |  Presenter: Niels Reinmuth

      • Abstract
      • Presentation
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

  • +

    Bristol-Myers Squibb - Industry Satellite Symposium

    • Type: Industry Satellite symposium
    • Presentations: 6
    • Coordinates: 4/10/2019, 18:15 - 19:15, Room A
  • +

    Immunotherapy in stage IV

    • Type: Educational session
    • Presentations: 6
    • Coordinates: 4/11/2019, 09:00 - 10:30, Room B
  • +

    Lunch & Poster Display session

    • Type: Poster Display session
    • Presentations: 170
    • Coordinates: 4/11/2019, 12:30 - 13:00, Hall 1
    • +

      56P - CT image standardization is superior to larger but heterogeneous data for robust radiomic models

      12:30 - 12:30  |  Presenter: Diem Vuong

      • Abstract

      Loading...

    • +

      82TiP - IMpower030: Phase III study evaluating neoadjuvant treatment of resectable stage II-IIIB non-small cell lung cancer (NSCLC) with atezolizumab (atezo) + chemotherapy

      12:30 - 12:30  |  Presenter: Solange Peters

      • Abstract

      Loading...

    • +

      101TiP - PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy

      12:30 - 12:30  |  Presenter: Nicolas Girard

      • Abstract

      Loading...

  • +

    ESMO-IASLC Best Abstracts

    • Type: Proffered Paper session
    • Presentations: 7
    • Coordinates: 4/11/2019, 14:45 - 16:15, Room B
    • +

      LBA1_PR - Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study

      14:45 - 15:00  |  Presenter: Taofeek K Owonikoko

      • Abstract
      • Presentation
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      LBA3 - Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs platinum-based chemotherapy (CT) based on clinical characteristics in patients with metastatic (m) NSCLC: Results from MYSTIC

      15:00 - 15:15  |  Presenter: Byoung Chul Cho

      • Abstract
      • Presentation
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

  • +

    Medscape Oncology - Industry Satellite Symposium

    • Type: Industry Satellite symposium
    • Presentations: 6
    • Coordinates: 4/11/2019, 18:00 - 19:00, Room C
    • +

      Introduction

      18:00 - 18:05  |  Presenter: Solange Peters

      • Abstract

      No abstract available for this presentation

    • +

      Conclusions and key points

      18:55 - 19:00  |  Presenter: Solange Peters

      • Abstract

      No abstract available for this presentation

  • +

    Do we treat patients with I-O until progression?

    • Type: Controversy session
    • Presentations: 5
    • Coordinates: 4/13/2019, 08:30 - 09:30, Room C